abstract: Oocyte maturation is associated with suppression of transcriptional activity. Consequently, gene expression during oocyte maturation, fertilization and early embryo development, until zygotic genome activation (ZGA) is primarily regulated by translational activation of maternally derived mRNAs. Embryonic poly(A)-binding protein (EPAB) is the predominant poly(A)-binding protein in Xenopus, mouse and human oocytes and early embryos prior to ZGA. EPAB plays a key role in polyadenylation-dependent translational activation of mRNAs by stabilizing polyadenylated mRNAs and by stimulating their translation. Epab-knockout female mice are sterile, fail to generate mature oocytes and display impaired cumulus expansion and ovulation. Consistent with its role during gametogenesis and early embryo development, Xenopus and mouse Epab mRNA is expressed exclusively in oocytes and early embryos, and is undetectable following ZGA or in somatic tissues. Herein, we demonstrate that although EPAB is expressed in human somatic tissues, its transcripts largely consist of an alternatively spliced form lacking the first 58 bp of exon 8, which leads to the formation of a premature stop codon 6 amino acids downstream on exon 8, and omission of the functionally critical poly(A)-binding domain. Moreover, 8-cell and blastocyst stage human embryos also express only the alternatively spliced form of EPAB. On the other hand, the full-length form of EPAB mRNA is exclusively expressed in oocytes. In conclusion, in contrast with the transcriptional regulation in Xenopus and mouse, oocyte-and early embryo-specific expression of EPAB in human is regulated by a post-transcriptional mechanism.
Introduction
During the development of the female gonad, oocytes differentiate from primordial germ cells, enter meiosis and become arrested in the prophase of the first meiotic division. Oogenesis is characterized by the synthesis and storage of mRNAs (reviewed in Song and Wessel, 2005) . The first meiotic arrest may last a few years in Xenopus and up to several decades in humans. Following sexual maturation, the hormonally mediated stimulation of oocyte maturation results in meiotic resumption and is associated with suppression of transcription in the oocyte. Consequently, during oocyte maturation, fertilization and early embryo development until zygotic genome activation (ZGA), which occurs at 2-cell stage in mouse and 4-8-cell stage in human (Clegg and Piko, 1982; Flach et al., 1982; Braude et al., 1988) , gene expression is regulated by translational activation and suppression of maternally derived mRNAs accumulated in the oocyte (Newport and Kirschner, 1982; Tadros and Lipshitz, 2009; Niakan et al., 2012) .
Cytoplasmic polyadenylation is the key mechanism by which translational activation occurs in the oocyte and requires a poly(A)-binding protein. Cytoplasmic poly(A)-binding protein (PABPC1), the predominant cytoplasmic poly(A)-binding protein in all somatic cells in vertebrates (Kozlov et al., 2001) , belongs to a family of RNA-binding proteins containing four highly conserved RNA recognition motifs (RRMs) and a poly(A)-binding (PAB) domain. Importantly, PABPC1 expression is minimal in oocytes and early embryos until ZGA (Seli et al., 2005) . Instead, a specific embryonic poly(A)-binding protein (EPAB) is the predominant poly(A)-binding protein in oocytes and early embryos until ZGA when it is replaced by PABPC1 (Voeltz et al., 2001; Seli et al., 2005; Guzeloglu-Kayisli et al., 2008) .
Initially discovered in Xenopus (Voeltz et al., 2001) , EPAB plays a key role in polyadenylation-dependent translational activation of mRNAs by binding the elongating poly(A) tail and promoting dissociation of Maskin (Cao and Richter, 2002) , by stabilizing polyadenylated mRNAs (Voeltz et al., 2001; Kim and Richter, 2007) and by stimulating their translation (Wilkie et al., 2005) , and is required for Xenopus oocyte maturation (Friend et al., 2012) . EPAB is also part of the complex that regulates polyadenylation-independent activation of RINGO/Spy mRNA in Xenopus oocytes (Padmanabhan and Richter, 2006) . In mouse, EPAB is required for female fertility and thus Epab-knockout female mice are sterile (Guzeloglu-Kayisli et al., 2012) . These mice do not generate mature oocytes, exhibit abnormal oocyte spindle formation and impaired cumulus expansion and ovulation (Guzeloglu-Kayisli et al., 2012) .
Recently, we and others have identified the human orthologue of mouse and Xenopus EPAB located on chromosome 20. The open reading frame of the full-length human EPAB is 1857 bp long and encodes a 619 amino acid protein Sakugawa et al., 2008) . Similar to other poly(A)-binding proteins, human EPAB is composed of two parts: an N-terminal domain that contains four RRMs that are required for RNA binding and a C-terminal PAB domain which functions in protein -protein interactions (Sachs et al., 1987; Mangus et al., 2003) . Human EPAB shows 77% identity and 84% similarity to the mouse EPAB, and 72% identity and 83% similarity to the Xenopus EPAB . However, unlike in Xenopus and mouse, human EPAB expression is detectable in somatic tissues in addition to the ovary and testis. Moreover, while Epab mRNA expression becomes undetectable in mouse embryos following ZGA, human embryos seem to express decreased, but detectable amounts of EPAB mRNA after maternal to zygotic transition (Cosson et al., 2002; Seli et al., 2005; Guzeloglu-Kayisli et al., 2008) .
Post-transcriptional regulation of gene expression includes mechanisms operating at the level of RNA processing, mRNA transport, translation, stability and protein processing (Sims and Reinberg, 2008; Hocine et al., 2010; Kanitz and Gerber, 2010) . Alternative splicing of mRNAs is one of the most important mechanisms of post-transcriptional modification. As a result of alternative splicing, tissue-specific isoforms, alternative intracellular localizations and altered biological functions of proteins may ensue. Recent studies based on RNA sequencing have shown that at least 90% of human genes undergo alternative splicing, resulting in the generation of variable transcripts from the same gene during RNA processing by alternative combinations of exons, retardation of introns and use of alternative 5 ′ and 3 ′ splice sites (Gardina et al., 2006; Wang and Burge, 2008; Kalsotra and Cooper, 2011) . Core splice signals are 5 ′ splice sites, 3 ′ splice sites and branch point sequences, and they are present in every intron. In addition, numerous cis-regulatory elements reside either in exons or introns, and enhance or inhibit (silence) splicing by interacting with trans-acting splicing factors (Wang and Burge, 2008) . In both mouse and human, EPAB is comprised of 14 exons and is subject to extensive alternative splicing (Seli et al., 2005; GuzelogluKayisli et al., 2008) . In the mouse, the alternatively spliced forms of Epab lacking exons 10, 13 or both have been reported . Importantly, the C-terminal PAB domain, which mediates critical protein -protein interactions is disrupted in the absence of exon 13 (Kozlov et al., 2001) . In human, there is alternative splicing of EPAB exon 9, or exons 9 and 10 (Guzeloglu- . Here, we show that in human somatic tissues, and 8-cell and blastocyst stage embryos, EPAB is spliced alternatively, by utilizing a cryptic donor acceptor site in the middle of exon 8, resulting in protein truncation and omission of the necessary PAB domain. In contrast, accurate splicing occurs in oocytes and results in full-length EPAB transcript similar to Xenopus and mouse. Our findings suggest that the oocyte-and early embryospecific expression of full-length EPAB in human is regulated posttranscriptionally, in contrast with the Xenous and mouse, where EPAB transcription seems to be suppressed following ZGA.
Materials and Methods

Collection of human oocytes and embryos
Oocytes and embryos were collected from consenting patients undergoing infertility treatment with in vitro fertilization (IVF) at Yale Fertility Center, New Haven, CT, USA. Institutional Review Board (IRB) approval was obtained prior to the initiation of the study. Controlled ovarian hyperstimulation was performed using a variety of protocols as previously published (Muasher et al., 2006) . Patients were monitored per established protocol and were judged to have sufficient follicular maturation when they had two or more follicles 18 mm or greater in maximal diameter. Oocytes were collected by transvaginal ultrasound-guided needle aspiration of the follicles under deep conscious sedation. Retrieved oocytes were rinsed, graded and placed in HEPES buffered human tubal fluid (HTF; Irvine Scientific, Santa Ana, CA) at 378C under 6% CO 2 in air. Conventional insemination or intra-cytoplasmic sperm injection was utilized as indicated.
On the day following oocyte retrieval and insemination (Day 1), each oocyte was examined for evidence of fertilization. Those that were found to have two pronuclei were placed into individual droplets of 30 ml Scandinavian G1 media (VitroLife) supplemented with 5% human serum albumin (HSA; Irvine Scientific) for culture to the cleavage stage (from Day 1 to 3). An embryo scoring system based on cleavage rate and morphology was used for the evaluation of embryo quality as previously described (Veeck, 1999) . In those cases, where 5-or more 4-cell Grade 1 or 2 embryos were present on Day 2, the embryos were placed into extended culture media [Scandinavian G2 media (VitroLife) supplemented with 5% HSA (Irvine Scientific)] and cultured until Day 5.
Immature oocytes that contain a germinal vesicle (GV) and mature metaphase II oocytes that failed to be fertilized after IVF were collected for analysis 24 h after the retrieval. Oocytes that underwent ICSI, or displayed morphologic changes consistent with decreased viability were not included in the study. Similarly, embryos at 8-cell and blastocyst stage that were donated to research were also collected. The 8-cell embryos were collected on post-fertilization Day 3, and the blastocyst stage embryos were collected on post-fertilization Day 5. Only embryos of highest quality based on morphologic assessment were included in the study. Informed consent in writing was obtained from each couple.
All oocytes and embryos were washed three times in sterile phosphatebuffered saline and transferred into 20 ml of SideStep lysis buffer solution (Strategene, La Jolla, CA). Samples were then frozen and stored at 2808C prior to RNA extraction. Experiments were repeated three times using 4 -10 oocytes or embryos for each analysis.
Isolation and reverse transcription of RNA from human oocytes and embryos Total RNA from oocytes or embryos was isolated using the PicoPure RNA isolation kit (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. RNA was treated with DNase I (Qiagen, Valencia, CA) to remove genomic DNA contamination. Reverse transcription was performed using RETROscript kit (Ambion, Austin, TX) in two steps: first, template RNA was incubated with random decamer primers at 858C for 3 min to eliminate any secondary structures, then a reverse transcription reaction was carried out at 428C for 1 h consisting of 2 ml of 10XRT buffer, 4 ml of 1.25 mM dNTP mix, 1 ml of RNase inhibitor (10 units/ml) and 1 ml of MMLV-RT (100 units/ml). Subsequently, inactivation of the MMLV-RT enzyme at 928C for 10 min was performed.
PCR amplification of human EPAB mRNA
The expression and splicing pattern of EPAB mRNA in human somatic and gonadal tissues was determined by PCR using human multiple tissue cDNA panels (Human MTC panel I and II, BD Biosciences, Clontech, Palo Alto, CA). Sequences and locations of all primers used in this study are given in Table I and Fig. 1A , respectively. In order to determine the expression of alternatively spliced forms of EPAB mRNA in human somatic tissues, oocytes and embryos, a hemi-nested PCR was performed. Primary PCR was performed using primers Exon1F and Exon8R. Amplifications were carried out in 25 cycles of PCR in which the initial 5 min denaturation at 958C was followed by a 'touch-down' program consisting of 10 cycles at 928C for 30 s, 608C for 30 s (218C per cycle) and 728C for 60 s; followed by 15 cycles of 928C for 30 s, 508C for 30 s and 728C for 60 s. A second round of PCR amplification was carried out using hemi-nested primers Exon5F/Exon8R or Exon5F/8R2. Amplifications for the second round were carried out in 35 cycles of PCR in which the initial 5 min denaturation at 958C was followed by a 'touch-down' program consisting of 10 cycles at 928C for 30 s, 658C for 30 s (218C per cycle) and 728C for 60 s; followed by 25 cycles of 928C for 30 s, 558C for 30 s and 728C for 60 s; and a final extension at 728C for 10 min.
As an internal control, the expression of a housekeeping gene, b-actin, was detected. All PCR products were separated on a 2% agarose/Tris borate EDTA gel and visualized using ethidium bromide staining. All EPAB amplification products were extracted using an Agarose Gel DNA Extraction Kit (Roche Applied Science, Indianapolis, IN) according to the manufacturer's protocol, and sequenced at the W.M. Keck Foundation Biotechnology Resource Laboratory at Yale University (New Haven). Sequencing results were compared with human EPAB transcript sequences using Sequencher software version 4.7 (Gene Codes, Ann Arbor, MI, USA).
Database search for splicing sites and exonic splicing enhancer elements
The Human Splicing Finder (http://www.umd.be/HSF/4DACTION/ input_SSF), NetGene2 Server (http://www.cbs.dtu.dk/services/; Brunak et al., 1991; Hebsgaard et al., 1996) and the splicing enhancer enhancer (ESE) finder program (version 2.0, http://rulai.cshl.edu/cgi-bin/tools/ ESE3/sefinder.cgi?Process=home; Cartegni et al., 2003) were used to identify the splicing sites and ESE consensus sequences.
Results
Full-length human EPAB is the only EPAB variant expressed in human oocytes
In order to further delineate the expression of EPAB and its splicing variants in human, we performed RT-PCR using primers on exons 5 and 8 (5F/8R) in somatic and gonadal tissues, and oocytes (Fig. 1A) . Interestingly, the size of the predominant band in oocytes was different from the one detected in somatic tissues (Fig. 1B) . Sequencing revealed that this band corresponds to the full-length EPAB mRNA. Conversely, somatic tissues such as kidney and liver primarily expressed an EPAB transcript that lacked the first 58 bp of exon 8. In ovaries, where both somatic cells and oocytes are present, both variants of EPAB mRNA were detected in comparable amounts (Fig. 1B and C) . It is noteworthy that the form lacking the first 58 bp of exon 8 results in a premature stop codon 6 amino acids downstream on exon 8 (Fig. 1D ) and the encoded protein lacks the fourth RRM (Ribonucleotide reductase M RRM4) and the PAB domain (Fig. 2) . Sequencing analysis further demonstrated that the other alternatively spliced forms of EPAB skipping exon 9 or both exons 9 and 10 previously identified in tissues other than oocytes , also lack the first 58 bp of exon 8 (data not shown). Therefore, as the deletion in exon 8 creates a new stop codon within the same exon, all alternatively spliced forms of human EPAB are predicted to encode truncated proteins that lack the fourth RRM and the PAB domain necessary for EPAB function.
Alternatively spliced form of EPAB is the predominant variant of EPAB expressed in somatic tissues
We evaluated the expression profile of the full-length and spliced form of EPAB mRNA in 13 different human tissues using nested PCR primers 5F/ 8R. The alternatively spliced form of this transcript was abundantly observed in all somatic tissues studied. However, weaker expression of the full-length EPAB was also detected in the lung, liver, kidney, spleen, thymus, colon, prostate and testis (Fig. 3) .
ZGA is followed by change in EPAB splicing pattern EPAB mRNA expression and alternative splicing were then evaluated in oocytes in comparison to early embryos by nested PCR using primers 5F/8R and 5F/8R2 (Fig. 4) . Primer 8R2 is located within the alternatively spliced part of exon 8 (Fig. 1A) . Full-length EPAB mRNA was detected in human oocytes. However, after ZGA, which occurs at the 4-8-cell stage in humans (Braude et al., 1988) , the splicing pattern changed, and 8-cell stage embryos and blastocysts utilized the splicing acceptor site in the middle of exon 8 ( Fig. 4A and B) . Therefore, only oocytes encode a functional form of EPAB. Following ZGA, alternative splicing of EPAB mRNA leads to the formation of a transcript, which encodes a truncated form of this protein.
The exon 8 of EPAB mRNA contains ESE motifs
Sequence analysis using two different prediction tools (see Materials and Methods) revealed that exon 8 contains two possible splice acceptor sites corresponding to the full-length transcript and the form lacking the first 58 bp of exon 8. Moreover, in silico analysis using ESE finder program revealed the presence of ESE motifs in the areas of exon 8 involved in alternative splicing (Fig. 5) . Top panel shows RT -PCR for EPAB with primers Exon1F and Exon8R. Middle panel shows nested PCR using Exon5F and Exon8R. Bottom panel shows control amplification of actin. The nested PCR demonstrates that all tissues predominantly express the alternatively spliced form of EPAB (392 bp). Weaker expression of the full-length EPAB mRNA (450 bp) is observed in the lung, liver, kidney, spleen, thymus, colon, prostate and testis. Actin is shown as an internal control. H, heart; B, brain; Pl, placenta; Lu, lung; Li, liver; Sm, skeletal muscle; Ki, kidney; Sp, spleen; Th, thymus; Te, testis; Si, small intestine; Co, colon; Pr, prostate.
Discussion
Since transcriptional activity is silenced during oocyte maturation and early embryo development, gene expression during this critical period of development relies on translational activation of mRNAs stored in the oocyte cytoplasm (Richter and Lasko, 2011) . Cytoplasmic polyadenylation is a key mechanism for translational activation of transcripts stored in the oocyte and requires a cytoplasmic poly(A)-binding protein (PABP). In Xenopus, mouse and human, EPAB is the predominant PABP in oocytes and early embryos until ZGA (Voeltz et al., 2001; Seli et al., 2005; Guzeloglu-Kayisli et al., 2008) . Interestingly, Epab is expressed exclusively in gonads, oocytes and early embryos in Xenopus and mouse (Voeltz et al., 2001; Seli et al., 2005) , while EPAB transcripts are detected in somatic human tissues .
In an effort to explore the regulation of tissue expression pattern of human EPAB compared with those seen in the mouse and Xenopus, we focused on the alternative splicing of EPAB; since alternative splicing is a key mechanism to generate tissue-or cell-specific forms of proteins (Montes et al., 2012) . We therefore amplified overlapping fragments of human EPAB spanning the entire length of the predicted EPAB sequence from human somatic and gonadal tissues, oocytes and early embryos. We sequenced, and compared the transcripts in an attempt to determine whether a post-transcriptional mechanism is utilized to control tissue and developmental stage-specific expression of EPAB in human. We found that an alternatively spliced form of EPAB lacking the first 58 bp of exon 8 is expressed in human somatic tissues and post-ZGA embryos. We also found that the previously reported splicing variants of human EPAB lacking exon 9 or both exons 9 and 10 (Guzeloglu-Kayisli et al., 2008) also lack the first 58 bp of exon 8. In silico analysis showed that the absence of first 58 bp of exon 8 results in a premature stop codon 6 amino acids downstream on exon 8.
In eukaryotes, the non-sense-mediated mRNA decay mechanism recognizes and degrades transcripts with premature stop codons (UAA, UAG, UGA) resulting from genomic mutations or aberrant RNA splicing (Maquat, 2005; Metzstein and Krasnow, 2006) . The alternatively spliced variants of EPAB are likely to be degraded by this cellular surveillance pathway. However, if translated, the alternatively spliced Epab transcripts would produce truncated proteins that lack the fourth RRM and the PAB domain. As the PAB domain is critical for proteinprotein interactions and provides a scaffold onto which other proteins can bind and mediate nuclear export, translation initiation and or mRNA stability (Mangus et al., 2003) , the truncated EPAB would not be functional. This prediction could be tested experimentally using the Epab-knockout mouse model (Guzeloglu-Kayisli et al., 2012) by determining if oocyte maturation and fertilization is rescued in Epab-deficient oocytes by introducing the truncated form of human EPAB. However, it is noteworthy that even the injection of the full-length mouse EPAB mRNA into immature (GV stage) Epab-knockout mouse oocytes does not rescue maturation, suggesting that EPAB function is required during earlier stages of oocyte development (Guzeloglu-Kayisli et al., 2012) . Therefore, we plan to perform rescue experiments with oocytes enclosed in early stage follicles. Once rescue is achieved, fulllength and truncated human EPAB will be tested in the same setting. Moreover, the expression of different forms of EPAB could be characterized further in human oocytes, embryos and somatic tissues once reliable EPAB antibodies are developed.
In contrast to the alternatively spliced form of EPAB seen in somatic human tissues, we found that human oocytes express only the full-length form of EPAB transcript, similar to its mouse orthologue expressed in oocytes and 1-cell and 2-cell embryos, prior to ZGA (Seli et al., 2005) . Importantly, while EPAB mRNA expression became undetectable at 4-cell stage and remained undetectable in 8-cell embryos and blastocysts by ESE finder. ESEs that are recognized by individual splicing regulatory proteins (SF2/ASF, SC35, SRp40 and SRp55) were identified by the ESE finder program. Threshold values are 1.956 for SF2/ASF, 2.38 for |SC35, 2.67 for SRp40 and SRp55. Thresholds represent values above which a score for a given sequence is considered to be significant (high score motif). Straight line below x-axis indicates the first 58 bp of exon 8.
in mouse, we observed a switch to the expression of the alternatively spliced truncated form in human following ZGA. Therefore, in human, alternative splicing of EPAB is differentially regulated in different tissues and at different time points during development and controls the expression of full-length EPAB.
It is unclear how the differential alternative splicing of EPAB occurs, as the mechanisms that control alternative splicing are still poorly understood. Specific exonic sequences can regulate RNA splicing in addition to their coding function (Zheng, 2004) . In this study, we identified five high-value ESE motifs in the region encompassing the first 58 bp of exon 8, which bind specific serine/arginine-rich splicing regulatory proteins (SR family proteins) to promote accurate splicing (Birney et al., 1993; Smith and Valcarcel, 2000) . SR-family proteins function in both constitutive and regulated pre-mRNA splicing. They can communicate with splicing co-activator SRm160/300 (Blencowe et al., 1998) . We have previously demonstrated that single nucleotide substitution in mouse EPAB mRNA can lead to the formation of ESE and preferential splicing . Different combinations of SR and SR-related proteins within tissues, oocytes and early embryos may function in conjunction with various ESEs in determining regulated patterns of splice site selection.
Our findings suggest that the full-length human EPAB mRNA is abundantly expressed in oocytes, while somatic tissues and post-ZGA embryos express predominantly the alternatively spliced forms which encode a non-functional protein. These results suggest that the expression of human EPAB as the predominant poly(A)-binding protein in oocytes is tightly regulated in human through a mechanism that is different from that observed in lower organisms. The implications of this regulatory switch through evolution remain to be investigated.
